查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931177

生命科学领域人工智慧市场：按组件、资料类型、部署方式、技术、最终用户和应用分類的全球预测（2026-2032年）

Artificial Intelligence in Life Sciences Market by Component, Data Type, Deployment, Technology, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生命科学领域的人工智慧 (AI) 市场价值将达到 110.9 亿美元，到 2026 年将成长至 129.4 亿美元，复合年增长率为 17.95%，到 2032 年将达到 352.5 亿美元。

关键市场统计数据
基准年 2025 110.9亿美元
预计年份：2026年 129.4亿美元
预测年份 2032 352.5亿美元
复合年增长率 (%) 17.95%

透过概述机会、科学驱动因素和决策者可采取的实际路径，为生命科学领域的人工智慧设定策略背景。

人工智慧不再只是生命科学领域的实验辅助手段，它已成为推动药物发现、开发、临床营运和患者照护等各个环节策略发展的驱动力。现代人工智慧方法融合了演算法进步、可扩展计算以及更丰富、更多样化的生物医学数据集，能够比传统工作流程更快地产生假设、优化标靶选择并提取具有临床意义的洞见。因此，领导者必须重新定义人工智慧，将其从技术投资转变为一项跨职能的变革，整合科学、监管和营运等各个领域。

整体情况正在重新定义生命科学组织如何发展治疗方法、管理数据和提供护理的变革性技术、监管和组织变革。

生命科学领域的人工智慧正从孤立的先导计画转向广泛的生态系统层面变革，这将重塑科学研究和医疗服务的提供方式。专用处理器、可扩展的云端基础设施和模组化软体堆迭的技术进步，使得建立大规模的模型和复杂的多模态分析流程成为可能。同时，自然语言处理和电脑视觉技术的进步，也为解读临床记录、病理切片和放射学研究开闢了新的途径，创造了以往难以实现的工作流程。

分析2025年美国关税对生命科学人工智慧供应链、运算资源采购和全球合作动态的累积影响

美国宣布将于2025年调整关税政策，将为全球生命科学供应链引入新的变数，并对人工智慧的应用产生累积效应。最直接的影响将体现在硬体采购方面，尤其是用于模型训练和推理的高效能处理器和加速器。关税上调将增加实际采购成本，并使供应商选择更加复杂，促使买家重新评估其整体拥有成本（TCO）和供应商多元化策略。

解读部署模型、元件、资料类型、最终使用者、技术和应用领域等方面的细微细分趋势，以指导产品和销售策略。

对市场区隔进行层级分解，可以揭示价值集中和营运风险集中的区域，从而为产品开发和商业策略提供明确的优先顺序。在考虑部署方案时，涵盖混合云端、私有云端和公共云端的云端环境能够提供所需的弹性和託管服务，加速模型实验。同时，当资料居住、延迟或特定监管限制需要本地管理时，本地资料中心部署仍然至关重要。决策框架应考虑能够平衡洞察速度和管治要求的混合架构。

区域情报整合了美洲、欧洲、中东和非洲以及亚太市场的创新生态系统、监管差异和采用速度。

区域趋势塑造着创新热点、不断演变的法规结构以及商业性应用的步伐。美洲地区环境多元化，领先的研究机构、大规模医疗系统和强大的创投生态系统推动快速的实验性创新。该地区的政策和报销趋势能够加速那些展现出临床效用和成本效益的解决方案的商业化进程，而各州和各系统之间的碎片化则使得互通性和灵活的应用模式显得尤为重要。

分析塑造人工智慧赋能的生命科学工作流程和伙伴关係的主要企业、新兴企业和平台供应商的策略行动和产品定位

引领人工智慧生命科学领域的公司正在采取独特的策略姿态，这反映了竞争与合作的演变。平台提供者和超大规模资料中心业者供应商强调整合式解决方案，透过提供託管运算、资料湖和模型运行工具来加速价值实现；而专业供应商则专注于垂直整合的解决方案，例如针对基因组学或放射学等特定领域的解决方案。Start-Ups通常专注于小众但影响巨大的应用场景，以快速检验临床效用并与大型企业建立合作关係。

为经营团队提供实用建议，帮助他们优先考虑投资、管治、技能和伙伴关係，以加速在生命科学领域安全、合规且商业性成功的AI应用。

领导者应优先考虑能够将技术潜力转化为持续的临床和商业性价值的投资和管治结构。首先，组织应采用以用主导的投资方法，将资源集中于具有高影响力的临床问题和可衡量的终点指标，而非探索性的功能集。这种方法可以减少浪费，并加快相关人员的接受度。其次，强制执行可重复性、可解释性和生命週期监管的管治框架可以降低监管和营运风险，并增强临床医生和患者之间的信任。

透明的调查方法，详细说明了用于建构人工智慧生命科学现状可靠图景的资料来源、分析框架、检验方法和品管。

该研究整合了来自行业领袖访谈、技术检验练习以及同行评审期刊、监管指南和已发布产品应用等二手文献的定性和定量证据。透过对资讯来源进行三角验证，确保结论反映了来自实践经验、技术基准和监管趋势的趋同证据。分析框架结合了技术堆迭观点、资料生命週期分析和市场推广路径规划，从部署模式、元件、资料类型、最终使用者、技术和应用领域等多个维度评估机会和风险。

这是一份综合性报告，提炼出医疗保健系统领导者、生物製药经营团队和研究机构需要关注的策略要务、风险缓解策略和后续步骤。

对现有证据的综合分析凸显了几个关键的持续挑战：将人工智慧投资与明确的临床和研究成果相匹配；加强对管治和可重复性的投入以满足监管要求；以及采用灵活的架构，在创新速度、数据主权和运营稳定性之间取得平衡。遵循这些原则的机构将更有能力将技术进步转化为研发流程、临床工作流程和病患疗效的可衡量改进。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 生命科学领域人工智慧市场（按组件划分）

  • 硬体
    • 处理器和加速器
    • 伺服器和工作站
    • 储存网路
  • 服务
    • 咨询
    • 一体化
    • 支援与维护
  • 软体
    • 平台
    • 解决方案
    • 工具和框架

9. 生命科学领域人工智慧市场（按资料类型划分）

  • 临床数据
    • 电子健康记录
    • 测试结果
  • 基因组数据
    • 基因表现数据
    • 定序数据
  • 影像资料
    • 电脑断层扫描
    • MRI
    • 超音波
    • X射线

第十章 生命科学领域人工智慧市场（以部署方式划分）

  • 云
    • 混合云端
    • 私有云端
    • 公共云端
  • 本地部署

第十一章 生命科学领域的人工智慧市场（按技术划分）

  • 电脑视觉
    • 三维重建
    • 医学影像分析
    • 模式识别
  • 机器学习
    • 深度学习
    • 强化学习
    • 监督式学习
    • 无监督学习
  • 自然语言处理
    • 语意分析
    • 语音辨识
    • 文字探勘
  • 预测分析
    • 预测结果
    • 风险建模
  • 机器人流程自动化

第十二章 生命科学领域人工智慧市场（按最终用户划分）

  • 合约研究机构
  • 医疗保健提供者
    • 诊所
    • 诊断中心
    • 医院
  • 製药和生物技术公司
  • 研究所

第十三章 生命科学领域人工智慧市场（按应用划分）

  • 临床试验管理
    • 资料管理
    • 病患招募
    • 测试设计
  • 诊断和影像诊断
    • 基因组成像
    • 病理影像诊断
    • 放射影像诊断
  • 药物发现
    • 先导药物最适化
    • 目标识别
    • 毒性预测
  • 病患监测
    • 远端监控
    • 穿戴式装置
  • 个人化治疗
    • 剂量优化
    • 精准医疗

第十四章 生命科学领域人工智慧市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 生命科学领域人工智慧市场（按地区划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国生命科学人工智慧市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国生命科学领域的人工智慧市场

第十八章：中国生命科学领域的人工智慧市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Atomwise
  • BenevolentAI
  • BioAge Labs
  • Cyclica
  • Exscientia
  • GNS Healthcare
  • Google Health
  • Healx
  • IBM Watson Health
  • Iktos
  • Insilico Medicine
  • Microsoft Corporation
  • NVIDIA Corporation
  • PathAI
  • Recursion Pharmaceuticals
  • ReviveMed
  • Schrodinger, Inc.
  • SOPHiA GENETICS
  • Standigm
  • Tempus Labs
  • Valo Health
  • Verily Life Sciences
  • XtalPi
  • Zephyr AI
Product Code: MRR-7B550E008D9D

The Artificial Intelligence in Life Sciences Market was valued at USD 11.09 billion in 2025 and is projected to grow to USD 12.94 billion in 2026, with a CAGR of 17.95%, reaching USD 35.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.09 billion
Estimated Year [2026] USD 12.94 billion
Forecast Year [2032] USD 35.25 billion
CAGR (%) 17.95%

Setting the strategic context for artificial intelligence in life sciences by framing opportunities, scientific drivers, and practical adoption pathways for decision-makers

Artificial intelligence is no longer an experimental adjunct in life sciences; it has become a strategic enabler that touches discovery, development, clinical operations, and patient care. Contemporary AI approaches combine advances in algorithms, scalable compute, and richer, more diverse biomedical datasets to create capabilities that accelerate hypothesis generation, refine target selection, and surface clinically actionable insights with greater speed than traditional workflows. As a result, leaders must reframe AI from a narrow technological investment to a cross-functional transformation that integrates scientific, regulatory, and operational domains.

Adoption pathways vary widely across organizations, but common drivers include the need to reduce time to insight, improve reproducibility, and manage exponentially growing volumes of genomic, imaging, and clinical data. Equally important are regulatory expectations for explainability and data provenance, plus the operational demands of deploying models where clinical and lab workflows intersect. Taken together, these forces require an approach that balances agility in innovation with disciplined governance, scalable infrastructure, and close collaboration among data scientists, clinicians, and compliance teams.

In the coming years, leaders who align technology choices with real clinical and research use cases will capture disproportionate value. This begins with a clear problem definition, iterative validation against high-quality data, and an organizational commitment to reskilling and cross-functional collaboration. By anchoring AI programs to measurable outcomes and robust risk management, institutions can realize practical benefits while maintaining patient safety and regulatory compliance.

Mapping transformative technological, regulatory, and organizational shifts that are redefining how life sciences organizations develop therapies, manage data, and deliver care

The landscape for AI in life sciences has shifted from isolated pilot projects to broad ecosystem-level changes that reshape how research and care are delivered. Technological progress in specialized processors, scalable cloud infrastructures, and modular software stacks is enabling much larger models and more complex multi-modal analytic pipelines. At the same time, advances in natural language processing and computer vision are unlocking new ways to interpret clinical notes, pathology slides, and radiology studies, thereby creating workflows that were previously impractical.

Regulatory frameworks and payer expectations are also evolving, prompting organizations to strengthen model validation, documentation, and post-deployment monitoring. This regulatory tightening acts as both a constraint and an opportunity: those that invest early in explainability, reproducibility, and lifecycle management gain a competitive advantage by reducing downstream friction and accelerating approval trajectories. Furthermore, the maturation of data stewardship practices and federated analytics approaches is changing competitive dynamics by enabling collaborative discovery without surrendering data control.

Organizationally, the shift toward productized AI requires new operating models that blend clinical domain knowledge with software engineering and data operations. Cross-functional platforms that standardize data ingestion, model development, and deployment pipelines reduce redundancy and accelerate value capture. As a result, companies are moving away from one-off solutions toward platform strategies that scale across therapeutic areas, clinical functions, and geographic markets.

Analyzing the cumulative effects of United States tariff measures announced for 2025 on AI supply chains, compute sourcing, and global collaboration dynamics in life sciences

Tariff policy changes announced for 2025 in the United States introduce a new variable into global life sciences supply chains that will have cumulative effects on AI deployments. The most immediate impact is on hardware sourcing, particularly high-performance processors and accelerators used for model training and inference. Increased tariffs raise the effective procurement cost and complicate vendor selection, encouraging buyers to reassess total cost of ownership and supplier diversification strategies.

Beyond hardware, tariffs influence the flow of preconfigured systems, storage arrays, and integrated platforms that are often supplied by global vendors. Organizations will likely respond by increasing use of local assembly, negotiating pricing adjustments, or shifting more workloads toward software-centric solutions that leverage cloud providers with localized data centers. These adjustments have implications for reproducibility and validation, because development environments may fragment across regions, requiring stronger configuration management and validation protocols to ensure consistent model behavior.

Tariff-driven changes also alter collaboration dynamics. Cross-border partnerships in areas such as multi-site clinical trials, federated learning initiatives, and contract research engagements may face additional administrative and logistical hurdles. As a result, stakeholders should expect longer procurement cycles, a renewed emphasis on supplier risk assessments, and potentially higher investments in interoperability and containerized deployment models that reduce dependence on specific hardware footprints. In sum, tariff policy becomes a strategic factor in architecture decisions, partner selection, and the economics of scaling AI in life sciences.

Interpreting nuanced segmentation dynamics across deployment models, components, data types, end users, technologies, and application areas to guide product and sales strategies

Decomposing the market through layered segmentation reveals where value and operational risk concentrate, and it suggests clear priorities for product development and commercial strategies. When considering deployment options, cloud environments-spanning hybrid cloud, private cloud, and public cloud-offer elasticity and managed services that accelerate model experimentation, while on-premise local data center deployments remain essential where data residency, latency, or specific regulatory constraints demand localized control. Decision frameworks should account for hybrid architectures that balance speed to insight with governance needs.

From a component perspective, hardware investments in processors and accelerators, servers and workstations, and storage and networking underpin performance, but they must be complemented by services such as consulting, integration, and support and maintenance to operationalize solutions effectively. Software layers that include platforms, solutions, and tools and frameworks are the connective tissue that turns compute into usable workflows; product teams must prioritize interoperability, extensibility, and modularity to reduce integration friction.

Data type segmentation underscores that clinical, genomic, and imaging datasets each present distinct technical and compliance challenges. Clinical datasets, including electronic health records and lab results, require robust de-identification and harmonization pipelines. Genomic data such as gene expression and sequencing outputs demand specialized storage, compute, and lineage tracking. Imaging modalities ranging from CT and MRI to ultrasound and X-ray necessitate high-throughput image processing and standardized annotation schemas to facilitate model training and cross-site validation.

End-user segmentation clarifies commercial routes to market and implementation pathways. Contract research organizations, split between clinical and preclinical CROs, pursue automation and predictive analytics to accelerate study timelines. Healthcare providers across clinics, diagnostic centers, and hospitals prioritize integration with clinical workflows and measurable impact on patient outcomes. Pharmaceutical and biotechnology companies, from biotech SMEs to large pharma, focus on drug discovery and translational pipelines. Research organizations, including academic laboratories and government institutes, often lead methodological innovation and data sharing initiatives.

Technology and application segmentation identifies where technical differentiation emerges. Computer vision capabilities such as 3D reconstruction, medical imaging analysis, and pattern recognition have immediate impact in diagnostics and imaging. Machine learning approaches spanning deep learning, reinforcement learning, supervised and unsupervised learning enable predictive modeling and adaptive trial designs. Natural language processing techniques including semantic analysis, speech recognition, and text mining unlock insights from clinical narratives. Predictive analytics applied to outcome prediction and risk modeling inform patient stratification and resource allocation. These technology building blocks map directly to applications like clinical trial management, where data management, patient recruitment, and trial design benefit from automation; diagnostics and imaging across genomic, pathology, and radiology domains; drug discovery functions such as lead optimization, target identification, and toxicology prediction; patient monitoring through remote devices; and treatment personalization, including dose optimization and precision medicine.

Regional intelligence synthesizing innovation ecosystems, regulatory divergence, and adoption velocities across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics shape where innovation concentrates, how regulatory frameworks evolve, and the pace of commercial adoption. The Americas represent a heterogeneous environment where leading research institutions, sizable healthcare systems, and a strong venture ecosystem drive rapid experimentation. Policy and reimbursement trends in this region can accelerate commercialization for solutions that demonstrate clinical utility and cost effectiveness, while fragmentation across states and systems places a premium on interoperability and adaptable deployment models.

Europe, Middle East & Africa presents diverse regulatory regimes and healthcare structures, which create both barriers and opportunities. In parts of this region, strong data protection norms and centralized health systems facilitate large, standardized datasets that can support robust model validation, whereas market fragmentation and variable digital maturity require flexible commercialization approaches. Collaborative initiatives across national boundaries and public-private partnerships often play a critical role in scaling pilots to national programs.

Asia-Pacific combines fast adoption of digital health technologies with strong manufacturing ecosystems for hardware and components. Several countries in this region have prioritized national AI and genomics strategies, which bolster investments in research infrastructure and public health analytics. The region also offers significant talent pools in software engineering and data sciences, enabling rapid development of localized solutions. However, regulatory heterogeneity and localization requirements mean that global vendors must adapt offerings to meet specific compliance and market access needs. Across regions, successful strategies reconcile global platform efficiencies with local implementation and regulatory nuances.

Profiling strategic behaviors and product positioning of leading companies, emergent challengers, and platform providers shaping AI-enabled life sciences workflows and partnerships

Companies shaping the AI life sciences landscape adopt distinct strategic postures that reveal how competition and collaboration will evolve. Platform providers and hyperscalers emphasize integrated stacks that reduce time to value by offering managed compute, data lakes, and model operationalization tools, while specialized vendors focus on verticalized solutions tuned to particular modalities such as genomics or radiology. Startups typically concentrate on narrow, high-impact use cases to validate clinical utility quickly and attract partnerships with larger incumbents.

Strategic alliances and commercial partnerships dominate go-to-market approaches, with technology vendors teaming with contract research organizations, health systems, and biopharma companies to co-develop and scale solutions. These partnerships often combine domain expertise, clinical access, and data resources from life sciences organizations with engineering, deployment, and support capabilities from technology firms. Consequently, licensing models, outcome-based contracts, and managed service offerings have emerged as important commercial constructs.

Open science and consortium models remain influential among research organizations and academic laboratories, facilitating method sharing and federated experiments that accelerate collective learning. Meanwhile, firms that invest in reproducibility, regulatory documentation, and post-market surveillance position themselves to capture more conservative buyers such as large pharmaceutical companies and health systems. Ultimately, the competitive landscape rewards companies that align technological capabilities with validated clinical outcomes and robust compliance frameworks.

Actionable executive recommendations that prioritize investment, governance, skills, and partnerships to accelerate safe, compliant, and commercially successful AI adoption in life sciences

Leaders must prioritize investments and governance mechanisms that convert technological potential into sustained clinical and commercial value. First, organizations should adopt a use-case driven investment approach that focuses resources on high-impact clinical problems and measurable endpoints rather than exploratory feature sets. This orientation reduces waste and accelerates stakeholder buy-in. Second, governance frameworks that mandate reproducibility, explainability, and lifecycle monitoring will reduce regulatory and operational risk and increase trust among clinicians and patients.

Third, talent strategies should combine targeted hiring with comprehensive reskilling programs so that clinicians, data scientists, and engineers can collaborate effectively. Cross-functional teams that balance domain expertise with software and data operations skill sets are essential for operationalizing models at scale. Fourth, architecture decisions must be pragmatic: hybrid deployments can leverage cloud agility while preserving local control for sensitive data, and modular software designs reduce integration overhead and enable rapid iteration.

Fifth, procurement and partner strategies should explicitly account for supply chain risk and tariff exposure by diversifying suppliers, favoring vendor neutrality in hardware dependencies, and negotiating service level agreements that include compliance and maintenance commitments. Finally, organizations should build measurement systems that tie AI initiatives to downstream clinical and financial outcomes, enabling continuous learning and clear ROI assessments that support sustained investment.

Transparent research methodology detailing data sources, analytic frameworks, validation approaches, and quality controls used to construct a reliable picture of the AI life sciences landscape

This research synthesizes qualitative and quantitative evidence from primary interviews with industry leaders, technical validation exercises, and secondary literature across peer-reviewed journals, regulatory guidance, and publicly disclosed product filings. Source triangulation ensured that claims reflect convergent evidence from practitioner experience, technical benchmarks, and regulatory trends. The analytical framework combined a technology stack view, data lifecycle analysis, and go-to-market mapping to evaluate opportunities and risks across deployment, component, data type, end user, technology, and application dimensions.

Validation activities included scenario testing of deployment architectures, sensitivity analysis of procurement pathways in the face of tariff changes, and cross-site model reproducibility checks using representative clinical and imaging datasets. Quality controls encompassed standardized interview protocols, independent code reviews of analytic scripts, and peer review of the narrative by subject matter experts in regulatory affairs, clinical operations, and data governance. Ethical considerations focused on data privacy, bias mitigation, and the implications of model error in clinical contexts.

Limitations are acknowledged where proprietary data or emerging regulatory decisions constrain definitive conclusions. Where appropriate, the research highlights assumptions underlying scenario analyses and identifies areas where additional primary data collection would strengthen confidence. The methodology is designed to be transparent and reproducible, enabling clients to request deeper dives or methodological appendices aligned to their specific evidence needs.

Concluding synthesis that distills strategic imperatives, risk mitigations, and next-step considerations for health system leaders, biopharma executives, and research institutions

Synthesis of the evidence points to several enduring imperatives: align AI investments with clearly articulated clinical or research outcomes, invest in governance and reproducibility to navigate regulatory expectations, and adopt flexible architectures that balance innovation speed with data sovereignty and operational stability. Organizations that follow these principles will be better positioned to convert technical advances into measurable improvements in discovery pipelines, clinical workflows, and patient outcomes.

Risk mitigation requires active management of supply chain exposures, especially in light of evolving trade policies that affect hardware and integrated systems. Similarly, talent scarcity and organizational friction can be overcome by deliberate reskilling programs and by embedding data operations into core business processes. Strategic partnerships remain a durable mechanism to access specialized expertise, accelerate validation, and scale solutions across institutions and geographies.

Looking forward, the interplay between model sophistication, data stewardship, and regulatory adaptation will determine how quickly AI moves from promising pilots to standard practice. Institutions that embrace cross-functional collaboration, robust measurement, and pragmatic technology choices will capture the greatest value while maintaining safety and public trust.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Intelligence in Life Sciences Market, by Component

  • 8.1. Hardware
    • 8.1.1. Processors & Accelerators
    • 8.1.2. Servers & Workstations
    • 8.1.3. Storage & Networking
  • 8.2. Services
    • 8.2.1. Consulting
    • 8.2.2. Integration
    • 8.2.3. Support & Maintenance
  • 8.3. Software
    • 8.3.1. Platforms
    • 8.3.2. Solutions
    • 8.3.3. Tools & Frameworks

9. Artificial Intelligence in Life Sciences Market, by Data Type

  • 9.1. Clinical Data
    • 9.1.1. Electronic Health Records
    • 9.1.2. Lab Results
  • 9.2. Genomic Data
    • 9.2.1. Gene Expression Data
    • 9.2.2. Sequencing Data
  • 9.3. Imaging Data
    • 9.3.1. CT Scans
    • 9.3.2. MRI
    • 9.3.3. Ultrasound
    • 9.3.4. X Ray

10. Artificial Intelligence in Life Sciences Market, by Deployment

  • 10.1. Cloud
    • 10.1.1. Hybrid Cloud
    • 10.1.2. Private Cloud
    • 10.1.3. Public Cloud
  • 10.2. On Premise

11. Artificial Intelligence in Life Sciences Market, by Technology

  • 11.1. Computer Vision
    • 11.1.1. 3D Reconstruction
    • 11.1.2. Medical Imaging Analysis
    • 11.1.3. Pattern Recognition
  • 11.2. Machine Learning
    • 11.2.1. Deep Learning
    • 11.2.2. Reinforcement Learning
    • 11.2.3. Supervised Learning
    • 11.2.4. Unsupervised Learning
  • 11.3. Natural Language Processing
    • 11.3.1. Semantic Analysis
    • 11.3.2. Speech Recognition
    • 11.3.3. Text Mining
  • 11.4. Predictive Analytics
    • 11.4.1. Outcome Prediction
    • 11.4.2. Risk Modeling
  • 11.5. Robotic Process Automation

12. Artificial Intelligence in Life Sciences Market, by End User

  • 12.1. Contract Research Organizations
  • 12.2. Healthcare Providers
    • 12.2.1. Clinics
    • 12.2.2. Diagnostic Centers
    • 12.2.3. Hospitals
  • 12.3. Pharmaceutical & Biotechnology Companies
  • 12.4. Research Organizations

13. Artificial Intelligence in Life Sciences Market, by Application

  • 13.1. Clinical Trial Management
    • 13.1.1. Data Management
    • 13.1.2. Patient Recruitment
    • 13.1.3. Trial Design
  • 13.2. Diagnostics & Imaging
    • 13.2.1. Genomic Imaging
    • 13.2.2. Pathology Imaging
    • 13.2.3. Radiology Imaging
  • 13.3. Drug Discovery
    • 13.3.1. Lead Optimization
    • 13.3.2. Target Identification
    • 13.3.3. Toxicology Prediction
  • 13.4. Patient Monitoring
    • 13.4.1. Remote Monitoring
    • 13.4.2. Wearable Devices
  • 13.5. Treatment Personalization
    • 13.5.1. Dose Optimization
    • 13.5.2. Precision Medicine

14. Artificial Intelligence in Life Sciences Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Artificial Intelligence in Life Sciences Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Artificial Intelligence in Life Sciences Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Artificial Intelligence in Life Sciences Market

18. China Artificial Intelligence in Life Sciences Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Atomwise
  • 19.6. BenevolentAI
  • 19.7. BioAge Labs
  • 19.8. Cyclica
  • 19.9. Exscientia
  • 19.10. GNS Healthcare
  • 19.11. Google Health
  • 19.12. Healx
  • 19.13. IBM Watson Health
  • 19.14. Iktos
  • 19.15. Insilico Medicine
  • 19.16. Microsoft Corporation
  • 19.17. NVIDIA Corporation
  • 19.18. PathAI
  • 19.19. Recursion Pharmaceuticals
  • 19.20. ReviveMed
  • 19.21. Schrodinger, Inc.
  • 19.22. SOPHiA GENETICS
  • 19.23. Standigm
  • 19.24. Tempus Labs
  • 19.25. Valo Health
  • 19.26. Verily Life Sciences
  • 19.27. XtalPi
  • 19.28. Zephyr AI

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DATA TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DEPLOYMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PROCESSORS & ACCELERATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PROCESSORS & ACCELERATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PROCESSORS & ACCELERATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVERS & WORKSTATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVERS & WORKSTATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVERS & WORKSTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY STORAGE & NETWORKING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY STORAGE & NETWORKING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY STORAGE & NETWORKING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY INTEGRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY INTEGRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY INTEGRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TOOLS & FRAMEWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TOOLS & FRAMEWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TOOLS & FRAMEWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DATA TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL DATA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL DATA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL DATA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL DATA, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ELECTRONIC HEALTH RECORDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ELECTRONIC HEALTH RECORDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ELECTRONIC HEALTH RECORDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY LAB RESULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY LAB RESULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY LAB RESULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC DATA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC DATA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC DATA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC DATA, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENE EXPRESSION DATA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENE EXPRESSION DATA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENE EXPRESSION DATA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SEQUENCING DATA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SEQUENCING DATA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SEQUENCING DATA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY IMAGING DATA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY IMAGING DATA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY IMAGING DATA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY IMAGING DATA, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CT SCANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CT SCANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CT SCANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HYBRID CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HYBRID CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPUTER VISION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPUTER VISION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY 3D RECONSTRUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY 3D RECONSTRUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY 3D RECONSTRUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MEDICAL IMAGING ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MEDICAL IMAGING ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MEDICAL IMAGING ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATTERN RECOGNITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATTERN RECOGNITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATTERN RECOGNITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MACHINE LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MACHINE LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REINFORCEMENT LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REINFORCEMENT LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REINFORCEMENT LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY UNSUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY UNSUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY UNSUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SEMANTIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SEMANTIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SEMANTIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SPEECH RECOGNITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SPEECH RECOGNITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SPEECH RECOGNITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TEXT MINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TEXT MINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TEXT MINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PREDICTIVE ANALYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PREDICTIVE ANALYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PREDICTIVE ANALYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY OUTCOME PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY OUTCOME PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY OUTCOME PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RISK MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RISK MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RISK MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HEALTHCARE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HEALTHCARE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT RECRUITMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT RECRUITMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT RECRUITMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TRIAL DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TRIAL DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TRIAL DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTICS & IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTICS & IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTICS & IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTICS & IMAGING, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATHOLOGY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATHOLOGY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATHOLOGY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RADIOLOGY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RADIOLOGY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY RADIOLOGY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TOXICOLOGY PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TOXICOLOGY PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TOXICOLOGY PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT MONITORING, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REMOTE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REMOTE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REMOTE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TREATMENT PERSONALIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TREATMENT PERSONALIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TREATMENT PERSONALIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TREATMENT PERSONALIZATION, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DOSE OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DOSE OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DOSE OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PRECISION MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PRECISION MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PRECISION MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DATA TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL DATA, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY GENOMIC DATA, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY IMAGING DATA, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DEPLOYMENT, 2018-2032 (USD MILLION)
  • TABLE 246. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLOUD, 2018-2032 (USD MILLION)
  • TABLE 247. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 249. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 250. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 251. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 252. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 254. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 256. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DIAGNOSTICS & IMAGING, 2018-2032 (USD MILLION)
  • TABLE 257. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 258. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY PATIENT MONITORING, 2018-2032 (USD MILLION)
  • TABLE 259. AMERICAS ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY TREATMENT PERSONALIZATION, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA ARTIFICIAL I